SCHEMBL3634740

SCHEMBL3634740

CCCC(=O)c1ccc(NCc2c[nH]nc2-c2cccs2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FRK P42685 1/20 0.46
CAMK2B Q13554 1/20 0.46
CAMK2G Q13555 1/20 0.46
CAMK2D Q13557 1/20 0.46
ADORA2A P29274 3/20 0.41
ADORA1 P30542 3/20 0.41
ADORA3 P0DMS8 2/20 0.41
SLC27A1 Q6PCB7 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
MAPT P10636 3/20 0.38
TP53 P04637 1/20 0.38
HDAC1 Q13547 4/20 0.37
HDAC2 Q92769 3/20 0.37
HPGD P15428 3/20 0.37
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 2/20 0.37
AHR P35869 1/20 0.37
HSD17B10 Q99714 1/20 0.37
HDAC3 O15379 1/20 0.36
NCOR2 Q9Y618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3636282 0.90 ADORA2A (0.41) FRKCAMK2BCAMK2GCAMK2DADORA2A
SCHEMBL3632674 0.84 SMN1; SMN2 (0.50) FRKCAMK2BCAMK2GCAMK2DSLC27A1
SCHEMBL4916251 0.83 MAPT (0.44) ADORA2AADORA1ADORA3MAPTTP53
SCHEMBL3635021 0.81 FRK (0.52) FRKCAMK2BCAMK2GCAMK2DSLC27A1
SCHEMBL3632565 0.81 FRK (0.52) FRKCAMK2BCAMK2GCAMK2DSLC27A1
SCHEMBL3640227 0.81 NR1H4 (0.45) L3MBTL1MAPTTP53HPGDKDM4E
SCHEMBL3640555 0.80 TP53 (0.47) FRKCAMK2BCAMK2GCAMK2DSLC27A1
SCHEMBL3634463 0.80 FRK (0.67) FRKCAMK2BCAMK2GCAMK2DL3MBTL1
SCHEMBL3633315 0.80 FRK (0.53) FRKCAMK2BCAMK2GCAMK2DL3MBTL1
SCHEMBL3639853 0.80 FRK (0.51) FRKCAMK2BCAMK2GCAMK2DL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242933-B2 Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) AbbVie Deutschland GmbH & Co. KG (DE) 2016-01-26 US claimed
US-9242933-B2 Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) AbbVie Deutschland GmbH & Co. KG (DE) 2016-01-26 US disclosed
EP-2167464-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) Abbott GmbH & Co. KG (DE) 2010-03-31 EP disclosed
WO-2008145616-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) ABBOTT GMBH & CO. KG (DE) 2008-12-04 WO disclosed
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) GRM2, GRIN2C, GRM1 FRK 2372/4885CAMK2B 250/4885CAMK2G 288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.